We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

Regeneron will no longer be 23andMe’s new owner. Previously it had been reported that 23andMe’s new buyer, paying $256 million for the company’s assets, ...

After Foley Hoag’s prior updates regarding the chapter 11 bankruptcy cases of 23andMe Holding Co and its affiliated debtors ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron had previously been the winning bidder in a bankruptcy auction for virtually all of 23andMe’s assets, but it's now lost out after bidding was reopened. Back to Top Albany Business Review ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe’s assets for $256 million in ...

23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

The case came after New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase 23andMe in a $256 million deal. That deal has since faced new challenges in ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder and former chief executive, Anne Wojcicki.